Market closed
Insmed/$INSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insmed
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Ticker
$INSM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,271
Website
Insmed Metrics
BasicAdvanced
$14B
-
-$5.57
1.11
-
Price and volume
Market cap
$14B
Beta
1.11
52-week high
$84.91
52-week low
$21.92
Average daily volume
1.8M
Financial strength
Current ratio
5.45
Quick ratio
4.994
Long term debt to equity
454.702
Total debt to equity
459.019
Interest coverage (TTM)
-9.24%
Management effectiveness
Return on assets (TTM)
-29.31%
Return on equity (TTM)
3,926.49%
Valuation
Price to revenue (TTM)
36.046
Price to book
50.24
Price to tangible book (TTM)
120.98
Price to free cash flow (TTM)
-18.575
Growth
Revenue change (TTM)
19.17%
Earnings per share change (TTM)
4.31%
3-year revenue growth (CAGR)
24.50%
3-year earnings per share growth (CAGR)
12.81%
What the Analysts think about Insmed
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Insmed stock.
Insmed Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Insmed Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Insmed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Insmed stock?
Insmed (INSM) has a market cap of $14B as of March 23, 2025.
What is the P/E ratio for Insmed stock?
The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of March 23, 2025.
Does Insmed stock pay dividends?
No, Insmed (INSM) stock does not pay dividends to its shareholders as of March 23, 2025.
When is the next Insmed dividend payment date?
Insmed (INSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Insmed?
Insmed (INSM) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.